-
2024-517457-27-00
5
2025-06-04
Chronic Obstructive Pulmonary Disease (COPD)
-
2023-506935-14-01
5
2025-06-01
Ischemic stroke
-
2024-519116-14-00
4
2025-05-27
Asthma
-
2023-506817-23-01
5
2025-05-23
Metastatic hormone naïve prostate cancer (mHNPC)
-
2024-517513-32-00
5
2025-05-16
Sjögren’s Syndrome
-
2023-506460-14-00
5
2025-05-07
Chronic kidney disease (CKD) and hypertension.
-
2023-507519-36-00
5
2025-04-29
Acne
-
2024-517582-16-00
5
2025-04-14
rapid sequence induction in the operating room
-
2024-512043-22-00
4
2025-04-11
Metastatic prostate cancer
-
2023-504086-23-00
5
2025-03-27
Subjects with PBC with a non-optimal response to UDCA.
-
2024-512729-10-00
4
2025-03-27
Recurrent or metastatic solid cancer harboring a FGFR1,2 ,3 fusion/rea
-
2023-508190-84-01
4
2025-03-13
Inflammatory disorders
-
2023-503326-39-00
5
2025-03-06
Synchronous oligometastatic non-small cell lung cancer (NSCLC)
-
2023-507873-16-00
11
2025-03-04
1st line treatment for unresectable metastatic colorectal cancer
-
2024-517419-62-00
4
2025-02-28
HER2 mutation
-
2023-509787-15-00
5
2025-02-17
Patients with localised prostate cancer and high-risk features of rela
-
2024-510772-20-00
4
2025-02-06
Rectal cancer locally advanced with microsatellite unstable or mismatc
-
2024-511652-40-00
5
2025-02-05
METASTATIC CASTRATION RESISTANT PROSTATE CANCER
-
2023-510322-32-00
5
2025-01-27
patients with incurable, metastatic/recurrent head and neck squamous c
-
2023-504554-35-00
5
2025-01-17
incisional hernia
-
2024-516372-14-00
11
2025-01-13
Asymptomatic Patients with frequent PVCs and normal LVEF
-
2023-508794-83-00
4
2025-01-10
Epidermolysis bullosa simplex
-
2023-509811-98-00
4
2025-01-07
Patients with HER2-positive locally advanced inoperable or metastatic
-
2023-506350-21-00
4
2025-01-06
Localized, resected, FIGO stage I (2018 classification), uterine leiom